Background. Screening tools for the identification of vulnerable older patients with cancer are needed. Aim of this study is to measure the prognostic value of multiple screening tools for the assessment of mortality risk in oncogeriatrics.
O
NCOLOGy is one of the clinical specialties that, more than others, has witnessed the aging of its patients, thanks the increasing number of early diagnoses and the availability of more effective interventions. The increased interaction between oncologists and geriatricians has led to the development of a novel subspeciality (ie, oncogeriatrics), specifically aimed at better evaluating the elders' overall health status, estimating their residual biological reserves, and optimizing therapeutic strategies.
The clinical assessment of physical function in elders is crucial for facilitating the development of person-tailored interventions. Unfortunately, there is a serious lack of evidence focused at trying to unify the available instruments into a single screening tool able to adequately capture the same condition of risk in cancer older patients (1) .
The available instruments (from both oncology and geriatrics) for the functional assessment of older patients may present different predictive capacities. Aim of the present hypothesis-generating analyses is to explore and compare the prognostic values for mortality of different physical function measures in older cancer patients.
Methods
Data are from 200 women aged ≥65 years old evaluated as part of a larger observational study (2) . All the present study participants referred to the Oncological Gynaecology Unit of the "Agostino Gemelli" University Hospital (a tertiary medical care center in Rome, Italy) for the design, planning, and subsequent conduction of their first line of therapy (after the oncological diagnostic process was locally or elsewhere completed). The baseline assessment was conducted by a multidisciplinary team of oncologists, gynecologists, and geriatricians, which took decisions for the subsequent clinical management of the patient.
All the patients signed a written informed consent. The local Ethical Committee approved the entire study protocol.
Mortality
Patients were followed for 12 months after the baseline assessment and monitored for the onset of major healthrelated events. If a death event occurred, details were retrieved from medical charts and participant's proxies.
Independent Variables of Interest
The Short Physical Performance Battery (SPPB) is composed by three timed tasks (ie, chair-stand test, balance test, and walking speed test), each one rescored from 0 (worst) to 4 (best) according to predefined cut-points (3). The total score (range 0-12) was used for the present analyses. The usual gait speed (UGS) was assessed over a 4-m course starting from a still position (4) . Participants unable to walk were considered as having a UGS = 0 m/s. The handgrip strength was measured using a Jamar dynamometer (Fred Sammons Inc., Burr Ridge, IL). The Eastern Cooperative Oncology Group Performance Status(5) is a six-level scale, ranging from 0 (Fully active, able to carry on all pre-disease performance without restriction) to 5 (Dead). The Karnofsky Performance Status (6) measures the patient's functional impairment as subjective percentage of wellbeing. It ranges from 100% (Normal, no complaints; no evidence of disease) to 0% (Dead). The Vulnerable Elders Survey-13 (7) is a screening tool (score range from 0 [absence of risk factors] to 10 [extreme vulnerability]) taking into account age, self-rated health, and physical impairments. The activities of daily living (ADL) scale (range 0-6, lower score indicates higher impairment) (8) explores the following tasks: eating, continence, dressing, personal hygiene, mobility, and use of the toilet. The instrumental ADL (IADL) scale (range 0-8, lower score indicates higher impairment) (9) includes ability to use the telephone, shopping, food preparation, housekeeping, laundry, transportation, responsibility for own medications, and ability to handle finances.
Covariates
The covariates considered in the present analyses included sociodemographic characteristics, cognition (Mini-Mental State Examination) (10), mood (15-item Geriatric Depression Scale) (11), body mass index, cancer characteristics, the "complexity score" of the Cumulative Illness Rating Scale (12), number of medications, pain and quality of life (measured by visuoanalogic scales, range 0 [worst] to 100 mm [best]), subsequent oncological interventions (ie, surgery, chemotherapy, radiotherapy, and/or palliative care), and biological parameters.
Statistical Analyses
Cox proportional hazard models were conducted to assess hazard ratios and 95% confidence intervals (95% CIs) for 1-year mortality for each performance measure. Results are shown per their standard deviations (SD) increases. Analyses were adjusted for age and all the variables showing a suggestive (p < .10) difference at univariate analyses. Analyses were conducted using SPSS software version 16.0 for Mac (SPSS Inc., Chicago, IL).
Results
Main characteristics of the sample (n = 200, mean age 73.5 [SD = 6.2] years) are reported in Table 1 . Twenty-three participants (11.5%) died during the follow-up. The most common primary sites of cancer were ovaries and utero, together accounting for more than 80% of the oncological diagnoses. Participants presented a median stage III of gynecological cancer with no significant differences between participants dying during the follow-up and survivors.
In Table 2 , results from Cox proportional hazard models predicting mortality from each performance measures are reported. The SPPB, UGS, and IADL were significantly associated with mortality. Such significant associations were confirmed even after adjustment for potential confounders, including cancer stage (Model 3). The strength of the associations was similar although slightly stronger for UGS and IADL. No statistically significant results were reported for the other measures of interest. Consistent results were obtained when grading, Cumulative Illness Rating Scale, or subsequent interventions were singularly included as additional covariates to the Model 3 (data not shown).
The areas under the curves at the receiver operating characteristic (ROC) analysis confirmed that only the UGS (0.686, 95% CI = 0.560-0.812, p = .007) and the IADL (0.676, 95% CI = 0.532-0.821, p = .01) had a statistically significant capacity to accurately predict mortality. A borderline significance was reported for the SPPB (0.638, 95% CI = 0.483-0.792, p = .05). The discriminatory capacity of the other tests was null (all ps > .1).
Discussion
Besides of confirming the prognostic value of the IADL (13), our findings showed significant results for two measures of physical performance (ie, SPPB and UGS) at predicting mortality in oncogeriatrics. In particular, results for the UGS are noteworthy given the clinically friendly design of the test.
The capacity of the UGS to identify community-dwelling older persons at increased risk of negative health-related events is well established in literature. Its adoption has recently started being considered in different clinical settings and medical disciplines. For example, Klepin and colleagues (14) tested the UGS as an independent predictor of disability and mortality in older persons with cancer. Similarly, slow UGS has been associated with incident dementia (15), higher risk of developing negative events related to high blood pressure (16) , and increased mortality in older patients undergoing cardiac surgery (17) . A recent systematic review has shown the importance of the gait speed in the assessment of older persons in different clinical settings (18) . Interestingly, the reported approximate 70% accuracy of the UGS in predicting survival at the receiver operating characteristic curve analyses is very similar to that provided by a complete clinical evaluation estimating the mortality risk in community-dwelling older persons (4). The identification of older patients at increased risk of negative health-related events may support clinical decisions, and indicate individuals requiring adapted interventions and follow-up. In this context, the capacity of the UGS to capture the individual's risk profile in the presence of major comorbidities, in a homogeneous population, and for a heterogeneous outcome (ie, overall mortality) strengthens its clinical relevance. In our study, we also reported significant results for the SPPB and the IADL. Differently from the SPPB, the UGS is more suitable for implementation in the daily clinical practice. Moreover, the predictive value of the two for negative health-related events has shown to be equivalent (3) . The IADL scale is more widely used than the UGS, but it relies on a subjective evaluation of the individual. Moreover, the inability to perform a functional task in elders is sometimes unrelated to physical capacity, but due to external factors (eg, social isolation, cultural background), potentially leading to wrong conclusions (19) .
The limited representativeness of our sample may affect a direct generalization of our findings (eg, to men, other oncological conditions, different clinical settings). The length of the follow-up may limit the applicability of these results to long-term endpoints. The relatively small sample size might have influenced our findings increasing the risk of false-negative findings. Finally, it is possible that variables not taken into account in the present analyses might differently explain our results.
The assessment of functional status in older cancer patients is at the basis of the oncogeriatric evaluation. The UGS represents a screening tool of special interest due to its easy clinical implementation, consistent results across cohorts/settings, and higher discriminatory value compared with other assessment instruments. Further studies are amenable to confirm and expand our findings.
